Skip to main content
Premium Trial:

Request an Annual Quote

Showdown, Though Not Quite at the OK Corral

Carl Icahn is taking another swing at Genzyme; he is going after four seats on Genzyme’s nine-member board — for himself and for three associates, reports the New York Times. Icahn has not said what his plans might be for Genzyme, though the Times notes that when Icahn wins seats on boards, chief executive officers tend to leave and Genzyme’s Henri Termeer isn’t expected to go without a fight. “I’m sure Henri will fight,” says former Genzyme director Constantine Anagnostopoulos. “But he will not fight if his fighting is detrimental to Genzyme. Genzyme is Henri’s baby.” In a statement, Termeer says that Genzyme would “welcome a constructive dialogue with Mr. Icahn.”

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.